Gentian Diagnostics ASA (DE:6FK) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gentian Diagnostics ASA reports a positive second quarter in 2024 with a 12% increase in sales and 13% organic growth compared to the same period in 2023. The company’s EBITDA also saw significant improvement, doubling from the previous year. Growth was driven by products such as fCAL® turbo, which experienced a 26% sales increase, and Cystatin C, with an 8% growth in the same quarter.
For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.